BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Dominating Today’s Market Action. BioCryst grew its share prices by 7.10 percent on Thursday to close at $9.81 apiece as investors repositioned portfolios following rumors that it is set to be acquired by a large-cap US biopharmaceutical company. The report first broke out on Monday from a website about deals and dealmakers, saying that a US-based pharmaceutical giant is setting its sights on BioCryst Pharmaceuticals Inc (NASDAQ:BCRX). ...

Core Viewpoint - Ten stocks experienced significant gains on Thursday, contrasting with a broader market decline, as investors favored companies perceived as less vulnerable amid ongoing geopolitical tensions in the Middle East [1]. Group 1: Stock Performance - Bloom Energy Corp. (NYSE:BE) saw a share price increase of 6.46% to close at $166.69, driven by rising energy demand and a shift towards alternative power sources due to geopolitical tensions [4][5]. - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) experienced a 7.10% rise in share prices to $9.81, attributed to acquisition rumors by a large-cap US biopharmaceutical company [7][8]. - Planet Labs PBC (NYSE:PL) shares jumped 8.76% to $26.96, buoyed by a positive revenue growth outlook for fiscal year 2027 despite previous earnings challenges [11][12]. - DLocal Ltd. (NASDAQ:DLO) saw a 9.43% increase in share prices to $12.53, following the achievement of over $1 billion in revenue for the first time, supported by strong total payment volume [17][18]. - Applied Optoelectronics Inc. (NASDAQ:AAOI) rallied 10.03% to close at $101.92, as investors returned to technology stocks benefiting from the AI sector [20]. Group 2: Financial Performance - Bloom Energy Corp. reported a net loss attributable to shareholders of $88.4 million, a 204% increase from $29.2 million in 2024, while revenues rose 37% to $2.02 billion from $1.47 billion year-on-year [6]. - BioCryst Pharmaceuticals Inc. turned a net income of $263.86 million in 2025, up from a net loss of $88.88 million in 2024, with total revenues soaring 94% to $874.8 million [9][10]. - Planet Labs PBC's revenues are projected to grow by 35% to 43% for the current fiscal year, targeting a range of $415 million to $440 million, despite a previous net loss of $242 million [12][16]. - DLocal Ltd. reported revenues of $1.09 billion, a 46% increase from $745.9 million in 2024, with net income rising 63.4% to $196.9 million [17][18]. - Applied Optoelectronics Inc. showcased a range of products aimed at AI systems, indicating a focus on high-performance solutions for evolving technology demands [21][24].

Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.'s share was trading at $9.30 as of March 16th. BCRX’s trailing and forward P/E were 7.69 and 109.89 respectively according to Yahoo Finance. Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns Copyright: zneb076 / 123RF Stock Photo BioCryst ...

Core Viewpoint - Avoro Capital Advisors LLC significantly reduced its stake in BioCryst Pharmaceuticals by 72.2% in Q3, indicating a shift in investment strategy towards the biotechnology company [2] Institutional Holdings - Avoro Capital Advisors LLC now holds 1,250,000 shares of BioCryst Pharmaceuticals, down from 3,250,000 shares, making it the 28th largest holding in their portfolio [2] - Arrowstreet Capital increased its position by 2,103.7% in Q2, now owning 4,278,555 shares valued at $38,336,000 after purchasing an additional 4,084,403 shares [3] - Qube Research & Technologies raised its stake by 152.3% in Q2, now holding 2,373,489 shares worth $21,266,000 [3] - Bank of America Corp DE grew its stake by 97.9% in Q2, owning 2,841,155 shares valued at $25,457,000 [3] - BNP Paribas Financial Markets lifted its position by 1,059.7% in Q2, now owning 1,456,857 shares valued at $13,053,000 [3] - Vanguard Group Inc. increased its position by 6.1% in Q3, now holding 21,790,881 shares valued at $165,393,000 [3] - Institutional investors collectively own 85.88% of BioCryst Pharmaceuticals [3] Stock Performance - BioCryst Pharmaceuticals stock opened at $8.22, with a 52-week low of $6.00 and a high of $11.31 [4] - The company has a market capitalization of $2.06 billion, a P/E ratio of 6.85, and a beta of 0.74 [4] - The stock's 50-day moving average price is $7.31, and the 200-day moving average price is $7.41 [4] Financial Performance - BioCryst Pharmaceuticals reported $1.12 earnings per share (EPS) for the last quarter, exceeding analysts' expectations of $0.07 by $1.05 [5] - The company had a net margin of 30.16% and a negative return on equity of 84.33% [5] - Revenue for the quarter was $163.28 million, up 209.1% compared to the same quarter last year, surpassing expectations of $151.32 million [5] Insider Activity - Insider Alane P. Barnes sold 21,773 shares at an average price of $7.65, totaling approximately $166,563.45, resulting in a 5.18% decrease in ownership [6] Analyst Ratings - Evercore issued an "outperform" rating with a target price of $17.00 [7] - Weiss Ratings upgraded the stock from "sell (d-)" to "hold (c)" [7] - HC Wainwright raised its price objective from $30.00 to $32.00, maintaining a "buy" rating [7] - Royal Bank Of Canada reduced its price objective from $14.00 to $13.00 while keeping an "outperform" rating [7] - The consensus rating for BioCryst Pharmaceuticals is "Moderate Buy" with a target price of $19.64 [7] Company Overview - BioCryst Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel oral small-molecule medicines for rare and serious diseases [8] - The company's first commercial product, Orladeyo (berotralstat), is approved for the prophylactic treatment of hereditary angioedema in the U.S. and Europe [9]

Core Viewpoint - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is identified as one of the top 10 most shorted biotech stocks to consider for investment, with a price target increase from $21 to $22 by Wedbush analyst Laura Chico, who maintains an Outperform rating on the stock [1][2]. Financial Performance - For the fourth quarter, BioCryst reported an EPS of $1.12, a significant improvement from a loss of $0.13 in the same quarter of the previous year [3]. - The company achieved revenues of $406.5 million for the quarter, up from $131.5 million year-over-year [3]. Business Development - The CEO, Charlie Gayer, highlighted that 2025 was a transformative year for the company, marking its first full-year profitability driven by strong commercial execution and the highest level of new patient prescriptions for ORLADEYO since its launch [3]. - BioCryst completed the acquisition of Astria Therapeutics, which is expected to enhance its hereditary angioedema (HAE) portfolio and support long-term growth [3]. Product Pipeline - BioCryst focuses on developing treatments for rare and hard-to-treat diseases, with significant products aimed at managing influenza and hereditary angioedema [4]. - The company is also advancing several promising new medicines in clinical trials in collaboration with major pharmaceutical partners [4].

BioCryst Pharmaceuticals FY Conference Summary Company Overview - **Company**: BioCryst Pharmaceuticals (NasdaqGS: BCRX) - **Key Products**: ORLADEYO, navenibart - **Recent Acquisition**: Astria Therapeutics Financial Performance - **2025 Revenue**: $601 million from ORLADEYO, $563 million after excluding European business sale - **Operating Profit**: $214 million non-GAAP operating profits - **2026 Guidance**: $625 million to $645 million, representing a 13% growth over the previous year [4][28] Product Insights ORLADEYO - **Launch Dynamics**: - ORLADEYO is the only oral prophylactic treatment on the market, differentiating it from injectables [12] - Approximately 50% of patients switching to ORLADEYO are coming from injectable therapies [12] - 60% of patients who try ORLADEYO remain on it after one year [8] - **Super-Responders**: - Over 50% of clinical trial participants remained on ORLADEYO for two years, showing a 91% reduction in attacks [7] - Patients prefer oral administration, leading to high retention rates among super-responders [34] - **Pediatric Launch**: - Approval for pediatric use in December, with expectations of significant adoption due to the convenience of ORLADEYO pellets [20] - Current pediatric treatment is underdiagnosed and undertreated, with only 40% of diagnosed children receiving prophylaxis [19] Navenibart - **Acquisition Rationale**: - Navenibart offers a long-acting injectable option, requiring only 2-4 injections per year, which is appealing to patients currently on more frequent injectable therapies [45] - Phase 1b/2 data shows a 92% reduction in attacks for 3-month dosing and 90% for 6-month dosing [46] - **Market Positioning**: - Navenibart is expected to attract patients currently satisfied with injectables due to its efficacy and reduced injection frequency [47] - The product is anticipated to launch within the existing BioCryst portfolio, leveraging established patient loyalty [58] Market Dynamics - **Patient Growth**: - The number of diagnosed HAE patients is growing at approximately 3% annually, with significant potential for further diagnosis and treatment [60] - Current estimates suggest around 1,100 pediatric patients should be diagnosed, with many still untreated [19][61] - **Competitive Landscape**: - The market is becoming increasingly competitive with new entrants, but BioCryst's established presence and patient loyalty provide a competitive edge [56] Future Outlook - **Long-Term Projections**: - BioCryst anticipates a revenue growth rate in the mid-teens through the 2030s, supported by strong patent protection for both ORLADEYO and navenibart [63] - The company is focused on maintaining operational efficiency without the need for additional sales or marketing teams for navenibart [64] - **Pipeline Developments**: - Ongoing studies for KLK5 inhibitor for Netherton's disease, with results expected by year-end [65][68] - Plans to enhance market-building activities upon successful drug development [72] Key Risks and Considerations - **Guidance Caution**: - The 2026 guidance is considered conservative due to the absence of last year's Medicare payer tailwinds and the sale of the European business [28][29] - **Market Adoption Uncertainty**: - The speed of pediatric adoption and the overall market response to navenibart remain uncertain [22][27] Conclusion - BioCryst Pharmaceuticals is positioned for growth with its unique product offerings and strategic acquisitions, although it faces challenges in market dynamics and patient adoption rates. The company’s focus on maintaining a strong pipeline and leveraging existing patient relationships will be crucial for its future success.

Core Insights - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) achieved profitability for the first time in its history, reporting a net income of $263.86 million in 2025, a significant turnaround from a net loss of $88.88 million in 2024 [2][4] - The company's total revenues increased by 94% year-on-year, reaching $874.8 million, driven by the successful sale of its European Orladeyo business for $243.3 million [2] - In Q4 2025, BioCryst reported a net income of $245.8 million, reversing a net loss of $26.79 million from the same period the previous year, with total revenues more than tripling to $406.5 million [3] Revenue and Sales Performance - For 2025, BioCryst is targeting total revenues between $635 million and $660 million, with approximately $625 million to $645 million expected from Orladeyo sales [5] - The company noted the highest level of new patient prescriptions in the US since the launch of Orladeyo, indicating strong commercial execution [4]

Group 1 - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is recognized as a promising small-cap stock with significant growth potential, receiving a Buy rating from Evercore ISI with a price target of $17.00 and a reaffirmed Buy rating from Bank of America Securities with a price target of $15.00 [1][2] - The company completed its acquisition of Astria Therapeutics, Inc. on January 23, which enhances its leadership in hereditary angioedema (HAE) and supports its long-term growth strategy [2] - BioCryst has added navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development, to its HAE portfolio, which aims to improve treatment experiences for HAE patients with potential dosing every three to six months [3] Group 2 - BioCryst Pharmaceuticals specializes in structure-guided drug design to develop oral small-molecule and protein therapeutics targeting rare diseases that are difficult to treat [4]

Product Development and Commercialization - The company is focused on the preclinical and clinical development of several product candidates, including ORLADEYO® (berotralstat) and others, with plans for commercialization in the U.S. and other markets[13] - The company anticipates additional regulatory approvals and milestones that could enhance revenue from product sales, including royalties and profit-sharing arrangements with partners[13] - The company is engaged in collaborations with partners such as Torii Pharmaceutical Co., Ltd. for ORLADEYO in Japan, which may impact its market presence and revenue generation[13] Financial Performance and Capital Management - The company aims to maintain sustained profitability and positive cash flow, although it acknowledges the need for potential future capital raises[18] - The company has never paid dividends on its common stock and does not anticipate doing so in the foreseeable future[336] - Future sales of common stock could lead to a decline in stock price and dilution of existing stockholders' ownership interests[330] Risks and Challenges - The company faces risks related to competition and the potential for generic versions of its products, which could adversely affect sales[19] - The company recognizes the complexities and risks associated with international market expansion, including regulatory compliance and operational challenges[295] - The company acknowledges the potential impact of external factors such as natural disasters and pandemics on its operations and business continuity[22] - Health epidemics or pandemics, such as COVID-19, could disrupt business operations and clinical development timelines, leading to increased costs and delays[310] - Unstable market conditions, including inflation and geopolitical instability, could adversely affect access to capital and overall business operations[314] - The company faces challenges in attracting and retaining key personnel, which is critical for product development and commercialization efforts[318] Operational and Compliance Issues - The company is subject to various international laws and regulations regarding data privacy, with potential fines of up to 4.0% of global revenues for noncompliance with GDPR[293] - The company is exposed to foreign currency exchange rate fluctuations, which could impact its consolidated operating results and cash flows[292] - The company emphasizes the importance of maintaining effective internal controls over financial reporting to ensure accurate financial statements[20] - The company identified and reported two material weaknesses in internal control over financial reporting in 2023, which were remediated by September 30, 2024[328] - Cybersecurity threats are increasing, with potential impacts on business operations and data integrity, which could result in significant costs and operational disruptions[301] - The company relies on third-party service providers for critical IT systems, increasing vulnerability to supply-chain attacks and potential data breaches[304] Market and Stockholder Dynamics - The company's stock price has been highly volatile, with a 52-week range from $6.00 to $11.31 per share for the twelve months ended December 31, 2025[326] - Approximately 47% of the company's common stock is owned by the top ten stockholders, allowing them to significantly influence corporate decisions[325] - As of December 31, 2025, there were 213,059,576 shares of common stock outstanding, with potential future dilution from stock options and restricted stock units[330] - Stockholder activism could divert management's attention from executing business strategy and adversely affect stock price[324] - The company has anti-takeover provisions that may complicate mergers or proxy contests[334] Strategic Decisions and Future Outlook - Future acquisitions or divestitures may divert management attention and could lead to dilution of stockholder value if not managed effectively[321] - The company may experience financial exposure related to divested businesses, including potential litigation and contingent liabilities[323] - The sale of the European ORLADEYO business may impact the company's ability to maintain global brand uniformity, affecting future growth and value realization[308] - The market for biotechnology securities is expected to remain volatile, influenced by various external factors including regulatory developments and public health concerns[331]

分组1 - BioCryst Pharmaceuticals reported quarterly earnings of $1.12 per share, significantly exceeding the Zacks Consensus Estimate of $0.07 per share, and compared to a loss of $0.13 per share a year ago, representing an earnings surprise of +1,623.08% [1] - The company achieved revenues of $406.56 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 172.17%, and this is a substantial increase from year-ago revenues of $131.53 million [2] - Over the last four quarters, BioCryst has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] 分组2 - The stock has underperformed the market, losing about 3.2% since the beginning of the year, while the S&P 500 has gained 1.5% [3] - The current consensus EPS estimate for the coming quarter is $0.08 on revenues of $158.52 million, and for the current fiscal year, it is $0.29 on revenues of $657.07 million [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the bottom 44% of over 250 Zacks industries, suggesting that the industry outlook can materially impact stock performance [8]